Clinical trials: Mild to Moderate COVID-19
Covid19
The Prevent Severe COVID-19 (PRESECO) Study
Double-blinded, placebo control, randomized, phase-3 clinical trial to evaluate clinical efficacy of Favipiravir in patients with mild to moderate symptoms related to COVID-19 infection
- Trial name
- PRESECO (NCT04600895)
- Testing
- Favipiravir
- Where
- 38 sites in United States, Brazil and 1 more
- Volunteers
- 1,187 people
- Sponsor
- Appili Therapeutics Inc.
COVID-19
Study to Assess the Efficacy and Safety of STI-1558 in Adult Subjects With Mild or Moderate (COVID-19)
This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy and safety of STI-1558 in adult subjects with mild/moderate COVID-19.
- Trial name
- NCT05716425
- Testing
- STI-1558
- Where
- 2 sites in China
- Volunteers
- 1,218 people
- Sponsor
- Zhejiang ACEA Pharmaceutical Co. Ltd.
COVID-19
The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients
This study is a multi-center, randomized, double-blind, parallel, placebo-controlled, phase Ⅱ clinical trial to evaluate efficacy and safety of Pyramax in mild to moderate COVID-19 patients.
- Trial name
- NCT04475107
- Testing
- Pyronaridine-Artesunate
- Where
- 13 sites in South Korea
- Volunteers
- 113 people
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
COVID-19
The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients (Phase3)
This study is a multi-center, randomized, double-blind, parallel, placebo-controlled, phase III clinical trial to evaluate efficacy and safety of pyramax in mild to moderate COVID-19 patients.
- Trial name
- NCT05084911
- Testing
- Pyramax
- Where
- 66 sites in Argentina, Chile and 4 more
- Volunteers
- 1,807 people
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
Olfactory and Taste Dysfunction in SARS-CoV2 Infection
EFFECT OF COVID-19 DISEASE IN SMELL AND TASTE OF PATIENTS WITH MILD, MODERATE OR SEVERE SYMPTOMATOLOGY
This is an observational data and recording study. The aim of our study is to investigate the effect of SARS-COV2 infection on patients' sense of smell and taste, through quality control measurements using optic analogue scale…
- Trial name
- NCT04657445
- Testing
- visual analogue scale
- Where
- Greece
- Volunteers
- 100 people
- Sponsor
- University Hospital, Ioannina
COVID-19, COVID-19 Acute Respiratory Distress Syndrome
Study of Cysteamine-pantetheine Disulfide (TTI-0102) in Mild to Moderate COVID-19
This is multi-center, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacodynamics (PD) and efficacy of TTI-0102 for the treatment of patients with mild to moderate COVID-19.
- Trial name
- NCT05212662
- Testing
- TTI-0102
- Sponsor
- Thiogenesis Therapeutics, Inc.
COVID-19, Long COVID
A Six-Month Follow-Up Study of Participants With Coronavirus Disease 2019 (COVID-19) Previously Enrolled in a RO7496998 (AT-527) Study
This study will evaluate the long-term sequelae of COVID-19 in patients diagnosed with COVID-19 who previously enrolled in a RO7496998 (AT-527) study (i.e.
- Trial name
- MEADOWSPRING (NCT05059080)
- Where
- 35 sites in Argentina, Belgium and 8 more
- Volunteers
- 72 people
- Sponsor
- Hoffmann-La Roche
Post COVID-19 Condition, Cognitive Impairment
Cognitive Impairment and Fatigue After Mild to Moderate COVID-19
The primary aim of the project is to map fatigue, cognitive and visual dysfunctions and possible underlying pathophysiological mechanisms in persons with long-term symptoms after a mild to moderate COVID-19 infection.
- Conditions
- Post COVID-19 Condition, Cognitive Impairment, Fatigue, Mental
- Trial name
- NCT06042530
- Testing
- Neuropsychological investigation, Optometric investigation, Magnetic Resonance Imaging
- Where
- Sweden
- Volunteers
- 100 people
- Sponsor
- Danderyd Hospital
Covid19
Study to Investigate the Clinical Efficacy of Isoquercetin in Patients With COVID-19
The purpose of this study is to investigate the clinical efficacy of Isoquercetin in preventing disease progression and symptoms improvement in mild-to-moderate hospitalised COVID-19 patients.
- Trial name
- NCT04733651
- Testing
- Hospital standard of care for COVID-19, Isoquercetin
- Volunteers
- 250 people
- Sponsor
- Nepal Health Research Council
Covid19
Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19
This is a phase 2 study in which subjects with coronavirus disease 2019 (COVID-19) will receive VIR-7831 (Sotrovimab) Generation 1 (Gen1) or VIR-7831 (Sotrovimab) Generation 2 (Gen2) and will be assessed for safety, tolerability…
- Trial name
- COMET-PEAK (NCT04779879)
- Testing
- Sotrovimab (Gen1), Sotrovimab (Gen2)
- Where
- 31 sites in United States, Canada and 3 more
- Volunteers
- 354 people
- Sponsor
- Vir Biotechnology, Inc.
COVID-19
Brequinar Combined With Dipyridamole in Patients With Mild to Moderate COVID-19
A Phase 2 multi-center, assessor-blind, randomized study to assess the safety, tolerability, and antiviral activity of brequinar in combination with dipyridamole.
- Trial name
- CCBCRISIS04 (NCT05166876)
- Testing
- Brequinar Sodium, Dipyridamole 75 MG
- Where
- 7 sites in India
- Volunteers
- 26 people
- Sponsor
- Clear Creek Bio, Inc.
COVID 19 Disease
Tafenoquine in Patients With Mild to Moderate COVID-19
A clinical study to assess the efficacy and safety of oral tafenoquine compared to placebo in patients with mild to moderate COVID 19 disease.
- Trial name
- NCT04533347
- Testing
- Tafenoquine Oral Tablet
- Where
- 10 sites in United States
- Volunteers
- 86 people
- Sponsor
- 60 Degrees Pharmaceuticals LLC
COVID-19, Children
Inhaled Interferon α2b Treatment in Mild-to-moderate COVID-19 Infected Children
In the COVID-19 pandemic era, a convenient and effective treatment for pediatric patients is unavailable. A multi-center Chinese clinical trials with the aim to using Interferon-α2b spray inhalation to develop new treatment…
- Trial name
- NCT05381363
- Testing
- Inhaled Interferon α2b, Standard of Care
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Children's Hospital of Fudan University
COVID-19
A Study to Evaluate the Efficacy and Safety of DXP604 in Patients With Mild to Moderate COVID-19
A phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of DXP604 in patients with mild to moderate COVID-19.
- Trial name
- NCT05381519
- Testing
- DXP604
- Volunteers
- 50 people
- Sponsor
- Wuhan Institute of Biological Products Co., Ltd
COVID-19
Study Evaluating SHEN26 Capsule in Patients With Mild to Moderate COVID-19
This is a multicenter, randomized, double-blind, placebo-parallel-controlled phase III clinical trial. It is designed to evaluate the efficacy and safety of SHEN26 capsules in Chinese adult patients with mild to moderate COVID-19
- Trial name
- NCT05908071
- Testing
- SHEN26 capsule
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Shenzhen Kexing Pharmaceutical Co., Ltd.
COVID-19
Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death
This is a multi-center, randomized controlled, superiority, open label trial. The objective of this trial is to evaluate the efficacy of HCQ in patients with newly diagnosed COVID-19 who have mild to moderate disease or at risk…
- Trial name
- NCT04323631
- Testing
- Hydroxychloroquine, The control group will not receive hydroxychloroquine
- Sponsor
- Rambam Health Care Campus
Covid19
Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting
No therapeutic agent is currently approved for the treatment of SARSCoV-2 infection. More importantly, no intervention is currently available to mitigate the progression of disease from mid/moderate to serve particularly in high…
- Trial name
- NCT04840459
- Testing
- BAMLANIVIMAB, CASIRIVIMAB, IMDEVIMAB
- Where
- 3 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Sohail Rao
COVID-19
Evaluation of the Safety and Efficacy of XoGlo Pro, a Placental Mesenchymal Stem Cell-derived Extracellular Vesicles in Treating COVID-19 Symptoms
Investigational New Drug trial investigating safety as primary endpoint and clinical efficacy as secondary endpoint of placental, mesenchymal stem cell-derived extracellular vesicles for the treatment of COVID-19 symptoms in…
- Trial name
- NCT07664696
- Testing
- IV infusion using an isolated, placental, mesenchymal stem cell derived EVs
- Volunteers
- 64 people
- Sponsor
- Kimera Labs Inc.
Covid19
Feasibility of Ayurveda in Patients With Mild-to-Moderate COVID-19: A Community-Based Participatory Research
Innovative strategies are required to manage COVID-19 in the communities. Back to Roots community based project was a collaborative, pilot intervention program in British Asian community to assess the efficacy and safety of…
- Trial name
- NCT04716647
- Testing
- Ayurveda
- Where
- United Kingdom
- Volunteers
- 28 people
- Sponsor
- Aarogyam UK
COVID-19 Pneumonia
Study of GST-HG171/Ritonavir Compared With Placebo in Patients With Mild to Moderate COVID-19
This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of GST-HG171/Ritonavir in the treatment of mild to moderate COVID-19.
- Trial name
- NCT05656443
- Testing
- GST-HG171/Ritonavir
- Where
- China
- Volunteers
- 1,246 people
- Sponsor
- Fujian Akeylink Biotechnology Co., Ltd.